Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
211At-MABG dose-escalation study in relapsed or refractory neuroblastoma
jRCT2021260055Phase 2Not yet recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of astatobenguane [211At] in neuroblastoma (5 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Dose-limiting toxicity, Maximum tolerated dose and 2 more. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
astatobenguane [211At]
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2021260055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021260055.